Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pedi
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
07:49am, Thursday, 16'th Sep 2021
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma (RCC), regardless o
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX® (cabozantinib) in combin
2 Top Biotech Stocks to Buy Right Now
11:45am, Saturday, 11'th Sep 2021
Both have underperformed the market recently. And both are primed for a comeback.
What's Happening With Exelixis Stock?
09:00am, Thursday, 09'th Sep 2021
A couple of months back we discussed that the stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, is best avoided after a negative outcome from its clinic
Is Exelixis Stock a Buy?
06:19am, Thursday, 02'nd Sep 2021
This biotech stock is down, but it's not out just yet.
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
07:51am, Thursday, 26'th Aug 2021
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan. The appr
4 Growth Stocks With 116% to 247% Upside, According to Wall Street
05:51am, Thursday, 26'th Aug 2021
Analysts' high-water price targets foresee these fast-growing stocks doubling or tripling in value.
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
12:08pm, Wednesday, 25'th Aug 2021
Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.
Exelixis (EXEL) Expands Oncology Collaboration With Invenra
09:53am, Tuesday, 17'th Aug 2021
Exelixis (EXEL) expands collaboration with Invenra to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development.
Exelixis, Invenra Expand Oncology Pact
03:47pm, Monday, 16'th Aug 2021
Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented partnership builds on the ongoing collabo
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
08:05am, Monday, 16'th Aug 2021
ALAMEDA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Invenra, Inc. today announced that they have expanded their discovery and licensing collaboration to include an addi
Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View
01:50pm, Friday, 06'th Aug 2021
Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q2 2021 Results - Earnings Call Transcript
10:29pm, Thursday, 05'th Aug 2021
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q2 2021 Results - Earnings Call Transcript
Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates
08:32pm, Thursday, 05'th Aug 2021
Exelixis (EXEL) delivered earnings and revenue surprises of 500.00% and 29.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
